DAE HWA Pharmaceutical Co. Ltd Net Assets
DAE HWA Pharmaceutical Co. Ltd net assets. Based on the latest financial reports, DAE HWA Pharmaceutical Co. Ltd (067080) has net assets worth ₩85.72 Billion KRW (≈ $58.09 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩220.34 Billion ≈ $149.32 Million USD) and total liabilities (₩134.61 Billion ≈ $91.23 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore DAE HWA Pharmaceutical Co. Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩85.72 Billion |
| % of Total Assets | 38.91% |
| Annual Growth Rate | 2.37% |
| 5-Year Change | -0.67% |
| 10-Year Change | 19.64% |
| Growth Volatility | 6.09 |
Net Assets of DAE HWA Pharmaceutical Co. Ltd (2011–2025)
Net assets of DAE HWA Pharmaceutical Co. Ltd from 2011 to 2025. This chart illustrates how DAE HWA Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. See DAE HWA Pharmaceutical Co. Ltd net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for DAE HWA Pharmaceutical Co. Ltd (2011–2025)
The table below shows the annual net assets of DAE HWA Pharmaceutical Co. Ltd from 2011 to 2025. For live market cap and overall valuation, see DAE HWA Pharmaceutical Co. Ltd market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩79.14 Billion ≈ $53.63 Million |
+9.92% |
| 2024-12-31 | ₩72.00 Billion ≈ $48.79 Million |
-1.68% |
| 2023-12-31 | ₩73.23 Billion ≈ $49.63 Million |
-6.10% |
| 2022-12-31 | ₩77.99 Billion ≈ $52.85 Million |
-2.11% |
| 2021-12-31 | ₩79.67 Billion ≈ $53.99 Million |
-2.81% |
| 2020-12-31 | ₩81.98 Billion ≈ $55.56 Million |
+3.32% |
| 2019-12-31 | ₩79.35 Billion ≈ $53.77 Million |
+3.21% |
| 2018-12-31 | ₩76.88 Billion ≈ $52.10 Million |
+0.16% |
| 2017-12-31 | ₩76.75 Billion ≈ $52.02 Million |
+16.03% |
| 2016-12-31 | ₩66.15 Billion ≈ $44.83 Million |
+8.35% |
| 2015-12-31 | ₩61.06 Billion ≈ $41.38 Million |
+4.36% |
| 2014-12-31 | ₩58.51 Billion ≈ $39.65 Million |
-5.68% |
| 2013-12-31 | ₩62.03 Billion ≈ $42.04 Million |
+1.04% |
| 2012-12-31 | ₩61.39 Billion ≈ $41.60 Million |
+7.73% |
| 2011-12-31 | ₩56.99 Billion ≈ $38.62 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to DAE HWA Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3831858062000.0% over the analyzed period, indicating profitable operations and earnings retention.
DAE HWA Pharmaceutical Co. Ltd Net Assets Breakdown (December 2025)
DAE HWA Pharmaceutical Co. Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩38.32 Billion | 51.73% |
| Other Components | ₩35.75 Billion | 48.27% |
| Total Equity | ₩74.07 Billion | 100.00% |
DAE HWA Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of DAE HWA Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Consórcio Alfa de Administração S.A
SA:BRGE3
|
$107.00 Million |
|
Multicampus Corporation
KQ:067280
|
$107.04 Million |
|
Riverview Bancorp Inc
NASDAQ:RVSB
|
$107.05 Million |
|
Borosil Scientific
NSE:BOROSCI
|
$107.06 Million |
|
IRM ENERGY LTD
NSE:IRMENERGY
|
$106.99 Million |
|
Mangata Holding S.A.
WAR:MGT
|
$106.93 Million |
|
WTK Holdings Bhd
KLSE:4243
|
$106.88 Million |
|
ANJI Technology Co. Ltd
TW:6477
|
$106.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DAE HWA Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 71,999,131,410 to 74,072,659,870, a change of 2,073,528,460 (2.9%).
- Net income of 1,653,508,840 contributed positively to equity growth.
- Dividend payments of 2,627,497,500 reduced retained earnings.
- Other factors increased equity by 3,047,517,120.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩1.65 Billion | +2.23% |
| Dividends Paid | ₩2.63 Billion | -3.55% |
| Other Changes | ₩3.05 Billion | +4.11% |
| Total Change | ₩- | 2.88% |
Book Value vs Market Value Analysis
This analysis compares DAE HWA Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.13x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.35x to 2.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩3746.41 | ₩8820.00 | x |
| 2017-12-31 | ₩4340.27 | ₩8820.00 | x |
| 2018-12-31 | ₩4347.40 | ₩8820.00 | x |
| 2019-12-31 | ₩4622.72 | ₩8820.00 | x |
| 2020-12-31 | ₩4692.74 | ₩8820.00 | x |
| 2021-12-31 | ₩4548.48 | ₩8820.00 | x |
| 2022-12-31 | ₩4452.48 | ₩8820.00 | x |
| 2023-12-31 | ₩4180.70 | ₩8820.00 | x |
| 2024-12-31 | ₩4110.33 | ₩8820.00 | x |
| 2025-12-31 | ₩4137.76 | ₩8820.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DAE HWA Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.16%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 2.85x
- Recent ROE (2.23%) is below the historical average (4.54%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 6.70% | 2.65% | 1.05x | 2.41x | ₩-1.85 Billion |
| 2012 | 5.23% | 2.20% | 1.10x | 2.16x | ₩-2.87 Billion |
| 2013 | 2.77% | 1.31% | 1.05x | 2.02x | ₩-4.36 Billion |
| 2014 | -0.18% | -0.08% | 1.09x | 2.14x | ₩-5.90 Billion |
| 2015 | 6.41% | 2.81% | 1.12x | 2.04x | ₩-2.19 Billion |
| 2016 | 5.64% | 2.62% | 0.93x | 2.33x | ₩-2.89 Billion |
| 2017 | 16.49% | 10.36% | 0.74x | 2.16x | ₩4.98 Billion |
| 2018 | 8.65% | 6.04% | 0.68x | 2.11x | ₩-1.04 Billion |
| 2019 | 13.28% | 9.20% | 0.69x | 2.09x | ₩2.61 Billion |
| 2020 | -2.45% | -1.84% | 0.62x | 2.14x | ₩-10.21 Billion |
| 2021 | 2.78% | 1.89% | 0.66x | 2.23x | ₩-5.75 Billion |
| 2022 | 1.43% | 0.85% | 0.66x | 2.55x | ₩-6.68 Billion |
| 2023 | -1.57% | -0.81% | 0.64x | 2.99x | ₩-8.47 Billion |
| 2024 | 0.74% | 0.36% | 0.73x | 2.86x | ₩-6.67 Billion |
| 2025 | 2.23% | 1.16% | 0.68x | 2.85x | ₩-5.75 Billion |
Industry Comparison
This section compares DAE HWA Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $608,670,163,398
- Average return on equity (ROE) among peers: -1.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DAE HWA Pharmaceutical Co. Ltd (067080) | ₩85.72 Billion | 6.70% | 1.57x | $107.00 Million |
| Dongwha Pharm.Co.Ltd (000020) | $360.13 Billion | 4.96% | 0.24x | $96.74 Million |
| Yuhan Corp. (000100) | $1.65 Trillion | 2.42% | 0.28x | $4.01 Billion |
| Yuhan Corp Preferred (000105) | $2.36 Trillion | 8.22% | 0.36x | $45.29 Million |
| Yuyu Pharma (000220) | $72.28 Billion | 2.26% | 0.33x | $40.85 Million |
| Yuyu Pharma Inc (000225) | $90.54 Billion | 5.22% | 0.52x | $13.36 Million |
| Yuyu Pharma Inc (000227) | $90.54 Billion | 5.22% | 0.52x | $29.54 Million |
| Ildong Holdings Co Ltd (000230) | $169.90 Billion | -35.07% | 4.16x | $42.86 Million |
| Samil Pharm (000520) | $62.27 Billion | 1.26% | 1.95x | $105.60 Million |
| Donga Socio Holdings (000640) | $998.66 Billion | 1.12% | 0.73x | $379.59 Million |
| Jw Pharmac (001060) | $230.09 Billion | -10.98% | 1.49x | $345.36 Million |
About DAE HWA Pharmaceutical Co. Ltd
DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea. The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthriti… Read more